Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications.
Stem Cell Reports 2017 Jul 11; 9(1):1-4
Pluripotent stem cells may acquire genetic and epigenetic variants during culture following their derivation. At a conference organized by the International Stem Cell Initiative, and held at The Jackson Laboratory, Bar Harbor, Maine, October 2016, participants discussed how the appearance of such variants can be monitored and minimized and, crucially, how their significance for the safety of therapeutic applications of these cells can be assessed. A strong recommendation from the meeting was that an international advisory group should be set up to review the genetic and epigenetic changes observed in human pluripotent stem cell lines and establish a framework for evaluating the risks that they may pose for clinical use. Stem Cell Reports 2017 Jul 11; 9(1):1-4.
Andrews, Peter W; Ben-David, Uri; Benvenisty, Nissim; Coffey, Peter; Eggan, Kevin; Knowles, Barbara B.; Nagy, Andras; Pera, Martin; Reubinoff, Benjamin; Rugg-Gunn, Peter J; and Stacey, Glyn N, "Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications." (2017). Faculty Research 2017. 138.